While leading clinicians celebrate this pleiotropic peptide for its well-documented safety and efficacy as a hypoglycemic agent and weight management tool, emerging studies suggest untapped therapeutic potential
Two major trials show the weight-loss drug offers no cognitive benefit to people with early Alzheimers, dashing hopes it might protect the brain
Ozempic and Mounjaro for Type 1 Diabetes: Why Aren't They Approved
Nutrient deficiencies, such as low iron or vitamin D, are also common contributors to fatigue
This similarity, including conserved residues such as glutamine, metal-binding sites, and hydrophobic regions within the binding pockets, often results in cross-target activity, limiting the success of selective therapies